NCI-2025-00431

A Phase 1b/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-Pantumor02)

The IDeate-Pantumor02 study is a Phase 1b/2, open-label, pan-tumor research study designed to test a new targeted therapy called Ifinatamab Deruxtecan (I-DXD) in people with recurrent or metastatic solid tumors—meaning cancers that have come back after treatment or have spread to other parts of the body. Ifinatamab Deruxtecan is an antibody-drug conjugate (ADC), which combines a monoclonal antibody that targets a specific protein on cancer cells with a powerful chemotherapy drug. This design allows the treatment to deliver the cancer-killing agent directly to tumor cells while limiting damage to healthy tissue. In this study, researchers are studying how well I-DXD works to shrink or control different types of advanced tumors, regardless of where they started in the body (hence “pan-tumor”). The study will also measure how long the treatment benefits last, how safe it is, and what side effects it may cause.

Open Label: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06330064

Clinical Trial Site: Sinai

To see all available clinical trials click here.